Takeda Pharmaceutical Company Limited

Martin Teall

Anne Goldby

Colm Carroll

Kerry Jenkins

Natasha Kinsella

Sarah Bousba

Stephen Mack

Kathryn White

Philip Mitchell

Gemma Liwicki

Anne Stephenson

Louise Dickson

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. in which q, R, R, Rand Rare as defined in the specification, for use in therapy.

Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R, R, Rand Rare as defined in the specification, for use in therapy.

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R, R, R, R, Rand Rare as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.

MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. 

Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R, R, R, Rand Rare as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease. 

Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R, R, Rand Rare as defined in the specification, compositions containing them and their use in therapy.

1-sulfonyl piperidine derivatives as modulators of prokineticin receptors

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R, R, Rand Rare as defined in the specification, compositions containing them and their use in therapy. 

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy. 

Piperidine and azepine derivatives as prokineticin receptor modulators

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. 

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: (I) in which m, n, W, X, Y, Z, R, R, Rand Rare as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conditions. 

Growing community of inventors

Cambridgeshire, United Kingdom

Martin Teall